ID   UKRV-Mel-02
AC   CVCL_A700
SY   UKRV-Mel-2; UKRV-MEL-2
DR   BTO; BTO_0005335
DR   cancercelllines; CVCL_A700
DR   Cosmic; 1846689
DR   Cosmic; 2163821
DR   Cosmic; 2686500
DR   ECACC; 13012436
DR   ESTDAB; ESTDAB-109
DR   Wikidata; Q54990556
RX   PubMed=7646526;
RX   PubMed=8688321;
RX   PubMed=15592718;
RX   PubMed=17311103;
RX   PubMed=19340423;
RX   PubMed=23348503;
RX   PubMed=23851445;
CC   HLA typing: A*01:01,25:01; B*08:01,18:01; C*07:01:01,12:04:02; DPB1*02:01:02,15:01; DQB1*06:02,02:01; DRB1*15:01,07:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ECACC=13012436; ESTDAB=ESTDAB-109
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 12,13
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,9
ST   FGA: 20
ST   TH01: 6,9.3
ST   TPOX: 10
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 24
//
RX   PubMed=7646526; DOI=10.1006/bbrc.1995.2187;
RA   Artuc M., Nurnberg W., Czarnetzki B.M., Schadendorf D.;
RT   "Characterization of gene regulatory elements for selective gene
RT   expression in human melanoma cells.";
RL   Biochem. Biophys. Res. Commun. 213:699-705(1995).
//
RX   PubMed=8688321; DOI=10.1038/bjc.1996.337; PMCID=PMC2074587;
RA   Schadendorf D., Fichtner I., Makki A., Alijagic S., Kupper M.,
RA   Mrowietz U., Henz B.M.;
RT   "Metastatic potential of human melanoma cells in nude
RT   mice -- characterisation of phenotype, cytokine secretion and
RT   tumour-associated antigens.";
RL   Br. J. Cancer 74:194-199(1996).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//